Tirzepatide Application Scope

Primary Indications:
- Type 2 Diabetes Mellitus (T2DM): Approved for improving glycemic control in adults with T2DM, used alongside diet and exercise 15.
- Obesity/Overweight: In clinical trials, Tirzepatide demonstrated significant weight loss (up to 22.5% of body weight) in non-diabetic obese/overweight patients, though this indication is pending regulatory approval in some regions 111.
- Potential Future Uses: Under investigation for cardiovascular diseases, NASH (non-alcoholic steatohepatitis), and sleep apnea 15.

Tirzepatide Characteristics

Ingredients: Synthetic dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors.
Properties: – Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈- Molecular Weight: 4813.45 g/mol- Appearance: Not specified (typically a lyophilized powder for injection).
Specification: Available in 5 mg, 10 mg, and 15 mg doses for weekly subcutaneous injection.
Packaging Specification: Pre-filled pens or vials (exact packaging details not specified in sources).
Storage: Store refrigerated (2–8°C) before use; may be kept at room temperature for a limited time after first use.
Expiry Date: Typically 24 months from manufacturing (check product labeling for exact dates).
Executive Standard: Manufactured under FDA (U.S.), EMA (EU), and NMPA (China) regulations.
Approval Number: – U.S. FDA Approval: May 2022 (Mounjaro®) .- China NMPA Submission: September 2022 (under review) .
Date of Revision: Latest clinical trial updates as of 2024 (SURPASS-CVOT expected in 2024).
Manufacturer: Eli Lilly and Company

Dosage and Administration: – Starting Dose: 2.5 mg once weekly, titrated every 4 weeks to 5 mg, 10 mg, or 15 mg based on glycemic response and tolerability.- Administration: Subcutaneous injection in the abdomen, thigh, or upper arm.
Adverse Reactions: Most common: Nausea, vomiting, diarrhea, constipation, decreased appetite, dyspepsia, abdominal pain (usually mild to moderate and transient).Less common: Hypoglycemia (when combined with insulin/SGLT-2 inhibitors), pancreatitis risk (rare) .
Contraindications: – Personal/family history of medullary thyroid carcinoma (MTC)- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)- Severe gastrointestinal disease (e.g., gastroparesis) .
Precautions: – Monitor for pancreatitis, gallbladder disease, renal impairment, and diabetic retinopathy complications– Not recommended in pregnancy or breastfeeding (insufficient safety data).

Drug Interactions: – Insulin/Sulfonylureas: Increased risk of hypoglycemia (dose adjustment may be needed)

Oral Medications: Delayed absorption possible (take oral drugs 1 hour before Tirzepatide)

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.